Neuromuscular expert Matthew Alexander, PhD, explores the evolving landscape of targeted therapies in muscular dystrophies, from fibrosis and glycosylation to combination strategies with gene therapy.
Matthew Alexander, PhD
Advertisement
Articles by Matthew Alexander, PhD
The associate professor of pediatric neurology and genetics at the University of Alabama Birmingham provided clinical insights on the key signaling pathways currently being targeted in the treatment of muscular dystrophies. [WATCH TIME: 4 minutes]
Advertisement
Latest Updated Articles
From Fibrosis to Function: Exploring New Pathways in Muscular Dystrophy ResearchPublished: April 19th 2025 | Updated:
Exploring New Avenues for Treating Muscular Dystrophies With Targeted Therapies: Matthew Alexander, PhDPublished: March 25th 2025 | Updated:
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Accepts New Drug Application for Tau PET Imaging Agent MK-6240 in Alzheimer Disease
2
Apomorphine Sublingual Film Displays Efficacy in Elderly Patients with Parkinson Disease
3
Exenatide Alters Motor Network Activity in Parkinson Disease, Though Clinical Impact Remains Limited
4
Expanding Patient Expectations When Managing Generalized Myasthenia Gravis: A Treating Physician’s Experience with IMAAVY™ (nipocalimab-aahu)
5
